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Ginna G. LaportFollicular lymphoma (FL) is the second most com-
mon type of non-Hodgkin’s lymphoma with an inci-
dence of 15,000 new cases/year in the United
States. The definite management of patients with FL
remains under considerable debate due to the numer-
ous treatment options available today. Such options
include observation, chemotherapy, external beam
radiation therapy, monoclonal antibodies, and radio-
immunoconjugates [1]. Hematopoietic cell transplant
(HCT) historically has been offered to younger
patients and/or patients with fairly advanced disease.
Autologous HCT (autoHCT) has unequivocally
shown improved disease-free survival in patients with
relapsed chemosensitive disease with 1 trial showing
an overall survival benefit [2,3]. For patients with FL
with relapsed disease, retrospective analyses have
shown that autoHCT can provide benefit for
patients who are not heavily pretreated before
autoHCT [4]. There is no role for autoHCT as con-
solidation therapy in first remission as 3 randomized
trials failed to demonstrate a survival advantage for
autoHCT compared to conventional therapy [5-7].
Allogeneic HCT (alloHCT) represents the only
treatment modality with curative potential for patient
with FL. In contrast to autoHCT, alloHCT utilizes
the graft vs lymphoma effect mediated by donor T cells
and an allograft ameliorates the tumor cell contamina-
tion potentially associated with an autograft. There
have been no completed randomized trials prospec-
tively comparing autoHCT to alloHCT. A large,
multicenter trial attempted to address this specific
question but closed early due to poor accrual [8]. How-
ever, both retrospective and prospective alloHCT
trials have consistently shown notably less relapse
rates compared to autoHCT [9-12]. Due to the
prohibitive nonrelapse mortality (NRM) associated
with myeloablative conditioning regimens, reduced
intensity conditioning (RIC) regimens have beenDivision of Blood and Marrow Transplantation, Stanford
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while utilizing the graft vs lymphoma effect as a form
of adoptive immunotherapy. Several studies utilizing
various RIC regimens have reported promising results
with event free survival and overall survival (OS)
ranging from 65% to 72% and 73% to 78%,
respectively, with follow-up durations ranging from 3
to 9 years [10-12].
In this issue of Biology of Blood and Marrow Trans-
plantation, investigators from the University of Mon-
treal report the results of 27 patients with relapsed
FL who received tandem autoHCT followed by RIC
alloHCT using matched sibling donors [13]. The
authors hypothesized that the high-dose chemotherapy
with autoHCT would confer intense cytoreduction
without the toxicity inherent with myeloablative
alloHCT. Patients would then achieve a minimal
disease state before proceeding to RIC alloHCT that
aimed to eradicate minimal residual disease via adop-
tive immunotherapy. The majority of patients had
chemosensitive disease but 19% were classified as
chemorefractory. Five patients had evidence of trans-
formed lymphoma and 7 patients were rituximab-
na€ıve. Despite these unfavorable characteristics, the
outcomes reported were impressive as the 3 year
progression-free survival and OS were 96%. The me-
dian follow-up was 39 months. The NRM incidence
was only 4% (1 patient died from graft-versus-host
disease-related complications) and no graft failures
were seen.
The concept of tandem auto/allo HCT is not
a novel concept as this modality has been utilized in
other lymphoma histologies and in multiple myeloma.
However, the tandemHCT trial in this issue is the first
report using tandem auto/alloHCT in patients with FL.
The progression-free survival and OS of 96% is re-
markable despite the fact that nearly 20% of patients
were chemorefractory. Chemosensitivity at the time of
alloHCT in patients with FL has been determined to
be the most powerful prognostic factor for survival after
alloHCT regardless of whether a myeloablative or RIC
regimen was administered [14]. These results beg the
question as to whether the intensive cytoreduction con-
ferred by the autoHCT may have facilitated the graft-
versus-lymphoma effect induced by the RIC alloHCT.
The notable results from this trial should be tem-
pered by specific issues raised by the investigators,
that the study design allowed patients to enroll and re-
ceive RIC alloHCT after autoHCT, which introduced
selection bias.
Biol Blood Marrow Transplant 18:819-821, 2012 821Tandem Transplantation for Follicular LymphomaTandem auto/alloHCT can now be added to the
expansive list of treatment options for patients with re-
lapsed FL. AlloHCT remains the only known cure for
relapsed FL. However, tandem auto/alloHCT also
carries obvious limitations as opposed to a single
HCT which include the considerable cost of a double
HCT and practical issues such as the lengthy time du-
ration that the patient and his/her caregiver must allot
for treatment and recovery time.
There is no consensus regarding the optimal timing
of either autoHCT or alloHCT for patients with re-
lapsed FL. Treatment choices must be individualized
based on factors such as comorbidities, age, perfor-
mance status, donor availability, andpsychosocial issues.
In summary, tandem auto/alloHCT for FL may
indeed offer the best of both worlds. Can an autoHCT
considerably augment the effects of RIC alloHCT and
thus overcome the negative prognostic outcome asso-
ciated with chemorefractory disease? This question
cannot be definitely answered based on a single
published series but may open the door for a larger,
confirmatory study especially for patients with chemo-
refractory disease.ACKNOWLEDGMENT
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